| Revenue growth | 13.7% YoY increase in Total Income. |
|---|---|
| Margins | EBITDA margin at 36.4%; PAT margin at 18.6%. |
| Demand visibility | High demand for drug discovery and electronics testing services. |
Growth
Revenue hit ₹1,129 Mn (up 13.7% YoY). PAT grew 11.4% YoY to ₹210 Mn.
Outlook
Invested ₹180 Mn in CAPEX during Q1; historical 4-year revenue CAGR stands at 10.5%.
Risks
Economic volatility, currency fluctuations, and increasing competition in the CRTO industry.
Last quarter's promises, checked
Delivered
- Guided 35% EBITDA margin → delivered 36.4% (= BEAT)
- Targeted double-digit revenue growth → delivered 13.7% (= BEAT)
- Maintain net debt-free status → delivered 0.01 D/E (= BEAT)
Partly delivered
- Commence Biologics services in FY27 → Started with ₹180 Mn CAPEX/infrastructure (= PARTIAL)
Missed
- Targeted ₹500 Cr annualized run rate by Q4 FY26 → delivered ₹416.3 Cr (= MISS)
Earnings Call filed with BSE, NSE: VIMTALABS. Summary written with AI assistance from the document.
Vimta Labs Ltd: key numbers
- Share price
- ₹567.20
- Market cap
- ₹2,535 Cr
- Revenue (annual)
- ₹407.3 Cr
- Net profit (annual)
- ₹77.51 Cr
- P/E (TTM)
- 31.8×Sector 53.1×
- Promoter holding
- 35.67%-0.18% QoQ
- FII holding
- 4.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vimta Labs Ltd
All →Vimta Labs Employee Stock Options
Vimta Labs allotted 12,955 ESOP shares under its 2021 plan. Paid-up capital rose to ₹8,93,99,718, raising dilution for shareholders.
Vimta Labs Credit Rating
CARE Ratings has reaffirmed the bank facility ratings of Vimta Labs Limited. The disclosure updates stakeholders on the company's ongoing credit facilities.
Vimta Labs Price Movement Clarification
Vimta Labs clarified that recent increases in its share volume are due to market factors and not related to any undisclosed company information or developments.
Vimta Labs Adverse Business Impact
Vimta Labs reported a cyber security incident affecting its IT infrastructure. The company confirmed operations remain fully functional with no material impact identified thus far.
Vimta Labs Investor Presentation: Key Takeaways
Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.
- Call
- Guides 25% growth
Vimta Labs Other Announcement
Vimta Labs Ltd filed its quarterly shareholding pattern disclosure for the period ending June 30, 2026, pursuant to SEBI Regulation 31(1)(b).